PMID- 30632192
OWN - NLM
STAT- MEDLINE
DCOM- 20190624
LR  - 20211204
IS  - 1600-0560 (Electronic)
IS  - 0303-6987 (Linking)
VI  - 46
IP  - 4
DP  - 2019 Apr
TI  - Differential expression of phospho-S6 in hair follicle tumors: Evidence of 
      mammalian target of rapamycin pathway activation.
PG  - 256-260
LID - 10.1111/cup.13411 [doi]
AB  - BACKGROUND: The role of the mammalian target of rapamycin (mTOR) in hair follicle 
      tumorigenesis is unclear. mTOR controls cell growth and can be activated through 
      ribosomal S6 kinase. Herein, we sought to evaluate the expression of phospho-S6 
      in six different benign and malignant follicular tumor types. METHODS: 76 cases 
      were selected (17 fibrofolliculomas, 20 trichoepitheliomas, 10 tricholemmomas, 19 
      pilomatricomas, 1 malignant proliferating tricholemmal tumor, 8 tricholemmal 
      carcinomas, and 1 trichoblastic carcinoma) and collected over 16 years. 
      Immunohistochemistry with monoclonal antibody for phospho-S6 was performed and 
      analyzed semi-quantitatively; statistical analysis using the chi(2) test was 
      performed, with P < 0.05 considered significant. RESULTS: All malignant neoplasms 
      in our series (8/8 [100%] cases of tricholemmal carcinoma, 1/1 [100%] 
      trichoblastic carcinoma, and 1/1 [100%] malignant proliferating tricholemmal 
      tumor) showed a strong and diffuse pattern of staining for phospho-S6 involving 
      70% to 90% of tumor cells. By contrast, a minority of benign tumors were positive 
      for phospho-S6 and most stained in a patchy pattern including 12/17 (71%) 
      fibrofolliculomas, 9/20 (45%) trichoepitheliomas and 1/10 (10%) tricholemmomas, 
      involving 30% to 50%, 5% to 20%, and 40% to 50% of tumor cells, respectively. 
      Most pilomatricomas (17/19 [89%]) exhibited a stronger, but distinctive staining 
      pattern, staining mostly the basaloid cells with a multifocal distribution, 
      involving 70% to 90% of tumor cells. CONCLUSIONS: Phospho-S6 is differentially 
      expressed among benign and malignant hair follicle tumors (P = 0.0044). While 
      malignant tumors show diffuse expression, only a small subset of benign neoplasms 
      were positive, primarily in a patchy distribution.
CI  - (c) 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
FAU - Sardina, Luis A
AU  - Sardina LA
AUID- ORCID: 0000-0002-4420-6997
AD  - Robert J. Tomsich Pathology and Laboratory Medicine Institute, Cleveland Clinic, 
      Cleveland, Ohio.
FAU - Rubin, Brian
AU  - Rubin B
AD  - Robert J. Tomsich Pathology and Laboratory Medicine Institute, Cleveland Clinic, 
      Cleveland, Ohio.
FAU - Jour, George
AU  - Jour G
AUID- ORCID: 0000-0001-8916-8966
AD  - Departments of Pathology and Dermatology, New York Langone Medical Center, New 
      York, New York.
FAU - Piliang, Melissa
AU  - Piliang M
AD  - Robert J. Tomsich Pathology and Laboratory Medicine Institute, Cleveland Clinic, 
      Cleveland, Ohio.
AD  - Department of Dermatology, Cleveland Clinic, Cleveland, Ohio.
FAU - Elston, Carly
AU  - Elston C
AD  - Robert J. Tomsich Pathology and Laboratory Medicine Institute, Cleveland Clinic, 
      Cleveland, Ohio.
AD  - Department of Dermatology, Cleveland Clinic, Cleveland, Ohio.
FAU - Bergfeld, Wilma F
AU  - Bergfeld WF
AD  - Robert J. Tomsich Pathology and Laboratory Medicine Institute, Cleveland Clinic, 
      Cleveland, Ohio.
AD  - Department of Dermatology, Cleveland Clinic, Cleveland, Ohio.
LA  - eng
PT  - Journal Article
DEP - 20190210
PL  - United States
TA  - J Cutan Pathol
JT  - Journal of cutaneous pathology
JID - 0425124
RN  - 0 (Biomarkers, Tumor)
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.11.1 (Ribosomal Protein S6 Kinases)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Biomarkers, Tumor/*analysis
MH  - Child
MH  - Child, Preschool
MH  - Female
MH  - Hair Diseases/*diagnosis/metabolism/pathology
MH  - Hair Follicle/metabolism/*pathology
MH  - Humans
MH  - Infant
MH  - Male
MH  - Middle Aged
MH  - Ribosomal Protein S6 Kinases/*analysis
MH  - Skin Neoplasms/*diagnosis/metabolism/pathology
MH  - TOR Serine-Threonine Kinases/metabolism
MH  - Young Adult
OTO - NOTNLM
OT  - hair follicle tumors
OT  - mTOR pathway
OT  - phospho-S6
EDAT- 2019/01/12 06:00
MHDA- 2019/06/25 06:00
CRDT- 2019/01/12 06:00
PHST- 2018/03/06 00:00 [received]
PHST- 2018/12/13 00:00 [revised]
PHST- 2018/12/23 00:00 [accepted]
PHST- 2019/01/12 06:00 [pubmed]
PHST- 2019/06/25 06:00 [medline]
PHST- 2019/01/12 06:00 [entrez]
AID - 10.1111/cup.13411 [doi]
PST - ppublish
SO  - J Cutan Pathol. 2019 Apr;46(4):256-260. doi: 10.1111/cup.13411. Epub 2019 Feb 10.